这是描述信息
Search
Submit
Cancel
Location:
Home
/
/
/
REGENECORE RC1416 Injection Approved for Clinical Trial Application in the United States

REGENECORE RC1416 Injection Approved for Clinical Trial Application in the United States

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2023-04-21
  • Views:0

(Summary description)Recently, Nanjing RegeneCore Biotech Co.,Ltd(hereinafter referred to as RegeneCore), a subsidiary of YOUNGY GROUP, independently developed the bispecific nanobody drug RC1416 injection, which has been approved for clinical trials by the US Food and Drug Administration (FDA), marking the synchronization of the product's clinical development strategy with the international market.

REGENECORE RC1416 Injection Approved for Clinical Trial Application in the United States

(Summary description)Recently, Nanjing RegeneCore Biotech Co.,Ltd(hereinafter referred to as RegeneCore), a subsidiary of YOUNGY GROUP, independently developed the bispecific nanobody drug RC1416 injection, which has been approved for clinical trials by the US Food and Drug Administration (FDA), marking the synchronization of the product's clinical development strategy with the international market.

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2023-04-21
  • Views:0
Information

Recently, Nanjing RegeneCore Biotech Co.,Ltd(hereinafter referred to as RegeneCore), a subsidiary of  YOUNGY GROUP, independently developed the bispecific nanobody drug RC1416 injection, which has been approved for clinical trials by the US Food and Drug Administration (FDA), marking the synchronization of the product's clinical development strategy with the international market. RC1416 is a recombinant anti human IL-4Ra and IL-5 single domain antibody injection that has been approved for clinical trials by the National Drug Administration on March 27 this year, with additional maintenance therapy for moderate to severe asthma as the indication.

 

RegeneCore is a leading innovative high-tech enterprise of YOUNGY GROUP in the field of nanobody medicine in China, committed to the research and development of innovative biological drugs of nanobody technology. At present, innovative research and development have been carried out for autoimmune diseases, tumors, etc., as well as research on coupling drugs and cell therapy products based nanobody.

 

Keyword:

Scan the QR code to read on your phone

TEL:

025-58608860

Address: Room 07 Building 16 Treehouse, No. 73, Tanmi Road, Jiangbei New District, Nanjing

Enterprise email:rjk@regenecore.com

 

这是描述信息

WeChat cooperative consultation

www.300.cn   nanjing   备案号:ICP18030131-1